Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Leuk Lymphoma. 2021 Apr 11;62(5):1167–1177. doi: 10.1080/10428194.2021.1910684

Figure 2. Potency of single-agent ruxolitinib and venetoclax against T-ALL lines.

Figure 2.

Trypan blue (A-B) and MTT proliferation data (C-D) of serially diluted ruxolitinib (A, C) and venetoclax (B, D) at 48 hours. Two independent experiments were performed with triplicate measurements. * p < 0.05; ** p < 0.01; *** p < 0.001.